

## Poly(ADP-Ribose) Immunoassay

### NCI Publications

---

#### [A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors](#)

Rajan A1, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. 2012. *Clinical Cancer Research* 18(8). p. 2344-51. PMID: 22371451

#### [A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas](#)

Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. 2012. *Clinical Cancer Research* 18(6). p. 1726-34. PMID: 22307137

#### [Modeling pharmacodynamic response to the poly\(ADP-ribose\) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells](#)

Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH. 2011. *PLoS One* 6(10). e-26152. PMID: 22028822

#### [Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas](#)

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH. 2011. *Cancer Research* 71(17). p. 5626-34. PMID: 21795476

#### [Histone \$\gamma\$ H2AX and poly\(ADP-ribose\) as clinical pharmacodynamic biomarkers](#)

Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y. 2010. *Clinical Cancer Research* 16(18). p. 4532-42. PMID: 20823146

#### [The statistics of phase 0 trials](#)

Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH. 2010. *Statistics in Medicine* 29(10). p. 1075-6. PMID: 20419759

#### [Phase 0 clinical trial of the poly \(ADP-ribose\) polymerase inhibitor ABT-888 in patients with advanced malignancies](#)

Kummar S, Kinders RJ, Gutierrez ME, Rubinstein L., Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H,

Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. 2009. Journal of Clinical Oncology 27(16). p. 2705-11. PMID: 19364967

[Phase 0 clinical trials team preclinical modeling of a Phase 0 clinical trial: qualification of a pharmacodynamic assay of poly \(ADP-ribose\) polymerase in tumor biopsies of mouse xenografts](#)

Kinders R J, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute. 2008. Clinical Cancer Research 14(21). p. 6877-85. PMID: 18980982

[Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.](#)

Kinders R, Parchment RE, Ji J, Kummar S, Murgu AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH. 2007. Molecular Interventions 7(6). p. 325-34. PMID: 18199854

[An enzyme-linked immunosorbent poly\(ADP-ribose\) polymerase biomarker assay for clinical trials of PARP inhibitors](#)

Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo Y, Giranda VL. 2008. Analytical Biochemistry 381(2). p. 240-7. PMID: 18674509